Tag: Big Pharma

Johnson & Johnson - J&J has completed the acquisition of Halda Therapeutics which is a clinical-stage biotechnology firm for an amount of $3.05bn in cash. This...

AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes...

Novartis, which is a leading global innovative medicines company, went ahead and announced on December 19, 2025, that it has reached an agreement along with...

The U.S. Food and Drug Administration – FDA on December 22, 2025, gave an approval to the first GLP-1 pill for obesity from Novo Nordisk,...

The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

A new agreement as per which Eli Lilly and Company is going to offer almost $40 million to Indiana University - IU has come...